IMPLEMENTING VALUE-BASED ONCOLOGY CARE AT EUROPEAN CANCER HOSPITALS

ONCOVALUE is a consortium of cancer institutes and commercial businesses that will work together to implement value-based oncology care to help improve cancer care by enabling and guiding cancer clinics to collect, harmonize and analyze high-quality Real World Data (RWD) in real-time and by developing an AI-based framework for assessing real-life effectiveness of novel cancer therapies in real-time.

Informed medical decisions

The consortium will also look to organize and maintain data collection as part of standard clinical routines by empowering and training health regulatory and health technology assessment (HTA) bodies to adopt RWD-driven methodologies in their decision-making on cost-effectiveness of novel cancer therapies. We will develop AI-based text analytics to extract and structure clinical information (oncologist’s evaluation of treatment response and adverse events) from free text and AI-based detection and analysis of response to treatment (disease progression vs. clinical benefit) from CT scans to be able to utilize vast amounts of unstructured outcome data of the metastatic target lesions for producing real world data. This will help assess and validate methods that can be systematically harnessed to help in personalized treatment selection utilizing large amounts of real world data.

Value-based assessment of novel cancer therapies

The efficacy of new therapies is often based on small studies with relatively little evidence for true value regarding outcomes, quality of life and cost-effectiveness. We want to achieve value-based assessment of novel cancer therapies and therefore ONCOVALUE will enable the inclusion of high-quality real-world data in regulatory and reimbursement decision-making. This will support the development of effective medicines, reduce spending on drugs that yield little benefit and enable oncologists to promote value-based cancer care. 

What ONCOVALUE aims to achieve

Widespread regulatory and Health Technology Assessment integration of real world data will lead to safer, more efficient, and affordable therapies, technologies, and digital solutions for (personalised) cancer care. ONCOVALUE contributes to increased cost-effectiveness and subsequent sustainability of cancer care. Systematic collection and evaluation of the patient-reported outcomes will lead to improved well-being. 

In the long-term, implementation of value-based cancer care at European cancer hospitals will aid in reducing the growing burden of cancer treatment.